Plain-English translation of NCT05257590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining two medications — nivolumab and — can help people with advanced, unresectable liver cancer. Nivolumab is already approved and helps the immune system fight cancer cells. is a new medication that may work together with nivolumab to stop cancer growth and prevent the cancer from spreading. Together, these medications may offer better results than either one alone.
Advanced liver cancer is difficult to treat, and many patients become resistant to existing therapies. This medication combination targets cancer in different ways, which could help control the disease better and give patients more treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive nivolumab by injection into your vein every two weeks and take as a pill by mouth twice daily. Treatment cycles last 28 days, and you would continue this combination as long as it is working and you are tolerating it well. Your doctor will monitor you closely with regular blood tests and imaging scans to check how you are responding and to watch for side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Taiwan